Cargando…

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies

SIMPLE SUMMARY: Immunotherapies offer broad potential to treat many diseases, including cancer. Macrophages are highly abundant immune cells, but are generally inhibited from eliminating tumor cells by ‘self’ signaling. Blocking this macrophage signaling checkpoint with antibodies has gone through c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrechak, Jason C., Dooling, Lawrence J., Tobin, Michael P., Zhang, William, Hayes, Brandon H., Lee, Justine Y., Jin, Xiaoling, Irianto, Jerome, Discher, Dennis E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026896/ https://www.ncbi.nlm.nih.gov/pubmed/35454837 http://dx.doi.org/10.3390/cancers14081930

Ejemplares similares

Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
por: Jalil, AbdelAziz R, et al.
Publicado: (2020)

Titrating CD47 by mismatch CRISPR-interference reveals incomplete repression can eliminate IgG-opsonized tumors but limits induction of antitumor IgG
por: Hayes, Brandon H, et al.
Publicado: (2023)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

Chromosomal instability can favor macrophage-mediated immune response and induce a broad, vaccination-like anti-tumor IgG response
por: Hayes, Brandon H., et al.
Publicado: (2023)

Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
por: Giatromanolaki, Alexandra, et al.
Publicado: (2022)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
por: Hutter, Gregor, et al.
Publicado: (2019)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
por: Behrens, Leonie M., et al.
Publicado: (2022)

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
por: Cabrales, Pedro
Publicado: (2019)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

Mechanosensing by the nucleus: From pathways to scaling relationships
por: Cho, Sangkyun, et al.
Publicado: (2017)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

‘Clustering’ SIRPα into the Plasma Membrane Lipid Microdomains Is Required for Activated Monocytes and Macrophages to Mediate Effective Cell Surface Interactions with CD47
por: Ha, Binh, et al.
Publicado: (2013)

Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis()()
por: Vaeteewoottacharn, Kulthida, et al.
Publicado: (2018)

Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages
por: Sakamoto, Mariko, et al.
Publicado: (2021)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts
por: Theocharides, Alexandre P.A., et al.
Publicado: (2012)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Augmentation of CD47/SIRPα signaling protects cones in genetic models of retinal degeneration
por: Wang, Sean K., et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
por: Xiao, Amy, et al.
Publicado: (2022)

Expression of Recipient CD47 on Rat Insulinoma Cell Xenografts Prevents Macrophage-Mediated Rejection through SIRPα Inhibitory Signaling in Mice
por: Teraoka, Yoshifumi, et al.
Publicado: (2013)

CD47-targeted cancer immunogene therapy: Secreted SIRPα-Fc fusion protein eradicates tumors by macrophage and NK cell activation
por: Billerhart, Magdalena, et al.
Publicado: (2021)

IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRPα, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRPα interaction and FcɣR engagement by simultaneously binding to CD47 and CD20 of B cells
por: Yu, Jifeng, et al.
Publicado: (2022)

Novel CD47: SIRPα Dependent Mechanism for the Activation of STAT3 in Antigen-Presenting Cell
por: Toledano, Natan, et al.
Publicado: (2013)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vfbs99s8adg2dmfbsg4p0h92va